.png){kind=icon}
.png){kind=icon}
Return
STAT3 signaling inhibitors for cancer treatment
.png){kind=icon}
PRE
AI
DOI：10.1016/j.tips.2026.07.004.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Constitutively activated Signal Transducer and Activator of Transcription 3 drives human cancer development and progression and represents a validated drug target. Signal Transducer and Activator of Transcription 3-targeting modalities have been developed, although low potency, poor physicochemical properties, and toxicity have limited their clinical development. Protein-degrader strategies are overcoming potency challenges and accelerating the preclinical and clinical development of Signal Transducer and Activator of Transcription 3-targeting modalities. Outcomes for Signal Transducer and Activator of Transcription 3-targeting agents in clinical trials show some promise and suggest that more work remains to be done. Signal Transducer and Activator of Transcription 3-targeting agents, when combined with other drugs and delivered at lower doses, could offer opportunities to enhance clinical benefits while limiting overall toxicity.
Journal
IF:
19.9
Papers:
3.3K
Citations:
1.5W